<DOC>
	<DOCNO>NCT02566876</DOCNO>
	<brief_summary>Abdominal pain ( AP ) -associated functional gastrointestinal disorder ( FGIDs ) , particularly Irritable Bowel Syndrome ( IBS ) Functional Dyspepsia ( FD ) , common pediatrics , safe effective treatment available . Although probiotic show promising result adult , study publish child . The Bifidobacterium Infantis , Bifidobacterium Breve Bifidobacterium Longum important beneficial bacteria child represent 95 % total bacterial population intestine breastfed infant . Objectives : 1 ) To evaluate effect oral administration mixture Bifidobacteria improvement frequency intensity AP child FD IBS . 2 ) To evaluate effect oral administration mixture Bifidobacteria quality life child FD IBS .</brief_summary>
	<brief_title>Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders</brief_title>
	<detailed_description>The study randomize , double blind , placebo-controlled , crossover trial conduct two pediatric tertiary care center Naples Foggia . All child age 8-17 year refer IBS FD Pediatric Clinics two participate center January December 2014 eligible study . IBS FD diagnose use Rome III criterion pediatric FGIDs . The main exclusion criterion presence chronic organic gastrointestinal disease , assess full clinical history examination , initial laboratory investigation include complete blood cell count , erythrocyte sedimentation rate , C-reactive protein , serum amylase lipase , tissue transglutaminase antibody , total serum immunoglubulins A , fecal calprotectin . Abnormalities test result patient 's exclusion study . Further exclusion criterion previous abdominal surgery , diseases affect bowel motility , concomitant psychiatric , neurological , metabolic , renal , hepatic , infectious , hematological , cardiovascular pulmonary disorder . Finally , patient use commercial preparation probiotic previous 3 month also exclude . The study articulate 16 week . After recruitment , patient enter 2 week-run-in phase evacuative frequency , stool feature gastrointestinal symptom record daily basis use questionnaire/diary provide study entry physician . At end baseline period , patient return center information regard AP characteristic , bowel habit associate symptom record use previously validate interviewer-administered questionnaire pediatric FGIDs . The `` Functional Disability Inventory '' ( FDI ) , second interviewer-administered validated questionnaire use assess physical psychosocial function investigate patient ' QoL . The instrument consist 15 item concern perception activity limitation past 2 week ; total score compute sum rating item . Total available score range 0 60 high score indicate great disability . After complete questionnaire , patient assign double-blinded fashion placebo intervention group accord computer-generated randomization allocation table . Participants randomize receive either 1 sachet per day mixture three Bifidobacteria ( namely , 3 billion Bifidobacterium longum BB536® , 1 billion Bifidobacterium infantis M-63® , 1 billion Bifidobacterium breve M-16V® ) , identical look taste placebo six week . No medication analgesic allow whole duration study . After complete six week treatment , preparation administer 2-week- '' washout '' period . Afterwards , patient switch group treat placebo probiotic period six week . At follow-up visit subject underwent complete physical examination , data record daily diary collect compliance treatment verify . Furthermore , FGIDs symptoms questionnaire FDI administer physician answer record . The main outcome parameter consider assessment efficacy administer treatment abdominal pain QoL . The investigator consider decrease FDI score least 75 % baseline score define relevant improvement QoL . Secondary outcome parameter change bowel habit IBS patient , effect test treatment nausea FD subject . The investigator involve recruitment follow-up patient , coordinate study analyze data , patient caregiver unaware randomization group phase study . The institutional ethical review board participate center approve study protocol . Written inform consent obtain parent legal guardian enrollment .</detailed_description>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Age 418years ; Diagnosis FD IBS pain accord Rome III criterion All parent legal tutor must sign informed consent document indicate awareness investigational nature study . Taking type probiotic 2 month prior enrollment Presence intestinal motility disorder Presence significant medical condition Presence previous abdominal surgery Inability unwillingness give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Children</keyword>
	<keyword>Abdominal Pain</keyword>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Quality Life</keyword>
</DOC>